Intellipharmaceutics Says Final FDA Approval has Not Yet been Issued for 5 MG Strength of Generic Dexmethylphenidate Generic of Focalin XR

Loading...
Loading...
Intellipharmaceutics
IPCI
advised that a final FDA approval has not yet been issued to the Company for the 5 mg strength of its generic dexmethylphenidate generic of Focalin XR(R). Although the Company has not received any indication from the FDA of a deficiency in its application for approval of the 5 mg strength, the Company has no further information as to when or if such final approval will be granted by the FDA
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...